澳门太阳集团www7722138-首页|welcome

About Us
About Haihe Biopharma

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide.

It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates.

As of today, Haihe Biopharma has received 18 IND or clinical trial approvals in four countries and regions.

Mission and Vision
Our Mission:
Inclusive and open to diversity,
innovation oriented to win together and benefit the mankind.
Our Vision:
Guided by biomarkers,
we aim to address the unmet clinical needs and provide patients
with safer and more effective innovative drugs.

 

Management Team
Company Milestones

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. 

  •  

    March 2022

     NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Glumetinib

  •  

    February 2022

    The NDA for Haihe Biopharma’s Glumetinib has been accepted for review by the CDE.

  •  

    January 2022

    U.S. FDA Grants Orphan Drug Designation to Haihe Biopharma’s Glumetinib for Treatment of NSCLC with MET Genomic Aberration

  •  

    March 2021

    Haihe established its Japan office

  •  

    July 2020

    Haihe completed
    Haihe completed worth
    1.2 billion yuan Series B Funding

  •  

    July 2020

    Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.

  •  

    December 2019

    Haihe established its US office

  •  

    October 2019

    Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan

  •  

    September 2019

    Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise
     

  •  

    April 2019

    Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer

  •  

    February 2019

    Haihe completed Haihe completed $136.6 million Series A Funding

  •  

    January 2019

    The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China

  •  

    September 2018

    Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical

  •  

    March 2018

    Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

Awards
2021
2020
2019
2018
XXX XXX
XXX
XXX
Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1